Veracyte Envisia Genomic Classifier Gets Medicare Coverage to Aid in Lung Disease Dx

Medicare administrative contractor Palmetto GBA MolDx has issued a final local coverage determination for use of its Envisia Genomic Classifier assay to clarify the diagnosis of patients with interstitial lung disease who are suspected of having idiopathic pulmonary fibrosis. According to the LCD policy, the Envisia test is intended to be used in patients for whom imaging results in an indeterminate or a probable UIP pattern, but not in patients without IPF or in patients who have a typical pattern of UIP.

The goal of the test, which analyzes expression of 190 genes, is to help clarify the diagnosis of UIP so that patients are not subjected to unnecessary lung biopsy surgeries.

Source: https://www.genomeweb.com/molecular-diagnostics/veracyte-envisia-genomic-classifier-gets-medicare-coverage-aid-lung-disease-dx